Phosphodiesterase-5 Inhibitors for Premature Ejaculation

Systematic Review and Meta-Analysis of Placebo-Controlled Trials

Bibliographic Data

ID21748375
AuthorsXuebao Zhang (0000-0003-2814-3516, Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China), Nan Chi (Department of Neurosurgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China), Miao Sun (0009-0000-3718-565X, Pharmaceutical Analysis Laboratory, Shandong Qidu Pharmaceutical Co., Ltd, Zibo, China), Zhengfei Shan (Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China), Yulian Zhang (0000-0003-0752-1522, Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China), Yuanshan Cui (0000-0002-6688-449X, Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China)
Year2020
Volume14
Issue3
Publication date2020-05-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueAmerican Journal of Men s Health (JOURNAL)
Journal identifiersISSN: 1557-9883 • E-ISSN: 1557-9891
PublisherSAGE Publications (PUBLISHER • US)
DOI10.1177/1557988320916406
LanguageEN
Citations received1
References cited31

The purpose of this analysis is to assess the efficacy and safety of phosphodiesterase-5 inhibitors (PDE5Is) for the treatment of premature ejaculation (PE). A comprehensive search was performed to ascertain from trials about PDE5Is for the treatment of PE and compare the results, including intravaginal ejaculatory latency time (IVELT), score of sexual satisfaction scale, and side effects, between the group treated with PDE5Is and that treated with placebo. Seven studies involving a total of 471 patients were included in this meta-analysis. This analysis showed that patients who were treated with PDE5Is had significantly increased IVELT (mean difference [MD] 2.60; 95% CI [1.85, 3.36]; p

Tools

Open DOISci-Hub